 |
 Video: What is a Stock Split?
|
|
|
| INmune Bio is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where the innate immune system is not functioning normally and contributing to the patient's disease. Co. has two product platforms: dominant-negative tumor necrosis factor, which utilizes dominant-negative technology and is being developed for Alzheimer's and treatment resistant depression and cancer and an out-licensing strategy for Duchenne's Muscular Dystrophy; and Natural Killer Cell Priming Platform, which utilizes a medicine approach for the treatment of a variety of hematologic malignancies, solid tumors and chronic inflammation. According to our INmune Bio stock split history records, INmune Bio has had 0 splits. | |
|
INmune Bio (INMB) has 0 splits in our INmune Bio stock split history database.
Looking at the INmune Bio stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into INmune Bio shares, starting with a $10,000 purchase of INMB, presented on a split-history-adjusted basis factoring in the complete INmune Bio stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
02/05/2019 |
|
| End date: |
05/02/2024 |
|
| Start price/share: |
$7.78 |
|
| End price/share: |
$11.13 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
43.04% |
|
| Average Annual Total Return: |
7.07% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$14,302.45 |
|
| Years: |
5.24 |
|
|
|
|
|
